De-risk your immuno-oncology drug development with HUB Organoids®

Immunotherapy has shown substantial success in cancer treatment, however, its efficacy is limited to only a subset of patients. Treatment failure can be attributed to the lack of predictive biomarkers, a high degree of heterogeneity in patient tumors, immunosuppressive tumor features, and the lack of clinically relevant models for preclinical testing.

Download this Infosheet to discover:

  • How HUB Organoids are superior preclinical models for immunotherapy drug development
  • HUB’s service offerings for CAR-T or engineered T cells, and bispecifics antibodies testing
  • Our Immuno-oncology biobanks including matched normal/tumor organoids and immune cells
  • Our established immune cell and tumor organoid co-cultures
contact us